CA-HYPERICE
8.11.2021 12:02:07 CET | Business Wire | Press release
Hyperice , a global high-performance wellness brand specializing in percussion, dynamic air compression, vibration, thermal technology, mind technology, and contrast therapy, today announced new investments from superstars across the sports world including professional golfer Rory McIlroy , Formula One (F1) driver Daniel Ricciardo , NHL player Connor McDavid , NBA player Klay Thompson and NBA player Jayson Tatum .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005407/en/
The new investors join an elite list of global athlete-investors such as 4-time tennis Grand Slam champion Naomi Osaka, football superstar Erling Haaland and Indian cricketer Virat Kohli as strategic investors, and quickly follows the company’s entry to mental wellness and evolution into a holistic high-performance wellness brand .
“I am a golfer first and foremost but I am also focused on the long game, which is why I chose to invest in Hyperice,” said professional golfer Rory McIlroy. “Hyperice is an important part of how I practice, play and recover. The company is doing incredible things to redefine and push holistic wellness, so it is an exciting and logical partnership for me and investment partners in Symphony Ventures.”
Other new athlete-investors include 2x NBA All-Star Jayson Tatum, 2x PGA TOUR Champion Tony Finau, 3x NBA Champion Klay Thompson, NBA Champion Khris Middleton, 6x MLB All-Star Nolan Arenado, MLB All-Star Matt Chapman, 4x MLB All-Star Justin Upton, World Series Champion Dexter Fowler, The Masters Champion Sergio Garcia, Professional BMX Athlete Nigel Sylvester, Master Trainer and Performance Specialist Joe Holder, top gaming personality Nicholas Kolcheff, known as NICKMERCS, and more.
These athletes join Hyperice’s current roster of existing high-performing athlete-investors such as Naomi Osaka, Seth Curry, Anthony Davis, Rickie Fowler, DeAndre Jordan, Jarvis Landry, Patrick Mahomes, Christian McCaffrey, Ja Morant, Chris Paul, Ben Simmons, Kelly Slater, Fernando Tatís Jr, J.J. Watt, Russell Westbrook and Trae Young.
“Hyperice’s full suite of products have made a big difference in my recovery and my entire approach to wellness,” said Formula One (F1) driver Daniel Ricciardo. “As Hyperice continues to expand, it felt like the right time to officially put my support into a company that I believe in.”
Now with a global footprint in more than 60 countries, Hyperice is experiencing dramatic global growth driven by an extensive athlete-investors roster, as well as global partnerships in China with the NBA and Leagues of Legends Pro League, the New Zealand national rugby team All Blacks, South Africa national rugby team Springboks, the Mexican Football Federation, and the Tottenham Hotspur Football Club in London.
Reigning National Hockey League (NHL) Most Valuable Player Connor McDavid added: “Hyperice products are a game changer when it comes to supporting both my physical and mental health. Hyperice is not only a brand I personally rely on, but it offers products that benefit all people, no matter what level of athlete they are.”
“This new group of strategic investors will help to fuel Hyperice’s global expansion,” said Jim Huether, Hyperice CEO. “Our international footprint continues to grow with products in more than 60 countries. Partnering with high-performing global athletes like Daniel Ricciardo, Rory McIlroy, Connor McDavid, in addition to the stacked roster we already have, helps continue to separate Hyperice as we continue bringing our innovative suite of products to a broader audience.”
Global Growth and Holistic High-Performance Wellness Brand Evolution
Hyperice recently announced a new stage of global growth as the company evolves into a holistic high-performance wellness brand. The multi-prong transformation, led by Hyperice’s recent acquisition of mental wellness company Core , its third acquisition in the last 18 months, is accompanied by a new brand identity and global brand campaign, and anchored by a suite of new products and industry-first technologies.
Among the new technology advancements include the world's first portable contrast therapy device, Hyperice X, and new generations of Hyperice’s wildly popular Hypervolt and Vyper lines, including the Hypervolt 2, Hypervolt 2 Pro, Vyper 3 and Vyper Go.
- Hyperice X : Last month, Hyperice introduced its latest innovation and the world's first portable contrast therapy device. Hyperice X creates a localized cycle of alternating heat and cold to the knee area for recovery and rehabilitation. Hyperice X will be available globally beginning in 2022.
- Hypervolt 2: The Hypervolt 2 offers noticeable updates from the original, including an improved ergonomic design and reduced weight. Three speeds of powerful percussion help give muscles the relief they’ve been asking for, every day.
- Hypervolt 2 Pro : With the Hypervolt 2 Pro, users will get the same powerful percussion massage therapy that the world’s best athletes have, right in the palm of their hand. Five speeds, set by a new adjustable dial, provide relief to stiff muscles, so users can train and recover like a pro.
- Vyper 3 : All systems activated. The Vyper 3 vibrating roller’s updated design and three speeds help to prime and warm-up the body with a powerful vibrating massage.
- Vyper Go : The next iteration of Hyperice’s “Go” line. Following the release of the Hypervolt Go in 2020, the Vyper Go is a portable, vibrating roller that helps activate muscles, so users can feel their best before activity at home or on the go.
The Vyper 3 is now available in Europe and the United States, and the Hypervolt 2, Hypervolt 2 Pro and Vyper Go are now available in Australia, Canada, China, Europe, New Zealand and the United States with other markets to follow.
Hyperice’s new modern approach and reimagined product innovation allows Hyperice to reimagine how it serves a broader audience of athletes and helps people everywhere do the things they love, and do it more.
For more information, visit hyperice.com. To purchase, please visit country-specific sites: Australia , Canada , China , France , Germany , Italy , New Zealand , Portugal , Spain , UK and the United States .
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies in 2021, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom